Sells molecular profiling tests using tissue and blood to help physicians select cancer treatments, and provides biopharma companies with molecular data and research services for drug development.
10-K for FY2025, filed Mar 3, 2026Our purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a…View ↗
Our molecular profiling solutions and the data generated by our multi-omic technology platform provide value to our biopharma partners…View ↗
Our Molecular Intelligence product portfolio consists of our MI Profile Platform, our whole exome sequencing (WES)/whole transcriptome…View ↗
Molecular profiling brings payments from patients, hospitals, and commercial or government insurers for tests, typically collected within 90 to 120 days of billing after results reach ordering physicians. Biopharma customers pay for research services over the service period, including through milestone payments and ongoing support.
10-K for FY2025, filed Mar 3, 2026For the majority of its molecular profiling services, the Company recognizes revenue from the sale of its precision oncology solutions…View ↗
The total consideration to which the Company expects to be entitled in exchange for the Company’s services may be fixed or variable.…View ↗
Contracts with biopharmaceutical customers may include multiple distinct performance obligations, such as molecular profiling services…View ↗
10-K for FY2025, filed Mar 3, 2026
FY2025 revenue by product or service ↗$812M
10-K for FY2025, filed Mar 3, 2026
$812M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Cost of services - Molecular profiling services
Sold outright
10-K for FY2025, filed Mar 3, 2026 |
94% |
Cost of services - Molecular profiling services, FY2025
$766.7M Sources
|
Sold outright |
|
Cost of services - Pharma research and development services
Recurring
|
5.6% |
Cost of services - Pharma research and development services, FY2025
$45.3M Sources
|
Recurring |
Treating physicians order clinical profiling, while biopharma companies and researchers use Caris's data and research services. International hospital systems are served through distributors or direct contracts.
10-K for FY2025, filed Mar 3, 2026Caris Assure is currently being offered for therapy selection as a laboratory developed test (“LDT”), and we have Medicare reimbursement…View ↗
Our purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a…View ↗
International DistributionView ↗
Not on paper. It lost $68.1M in FY2025, but brought in more cash than it spent: $66.9M of free cash flow.
10-Q for Q3 FY2026, filed Nov 4, 2026
Open tableView ↗
8-K, filed Aug 5, 2026
Raises 2026 revenue guidance to $1.03 to $1.04 billion, representing growth of 27% to 28%View ↗
Competes with Foundation Medicine, Tempus, Memorial Sloan Kettering Cancer Center, New York Presbyterian—Weil Cornell, Grail, Freenome, Guardant Health, Exact Sciences, Delfi Diagnostics, Natera, SAGA Diagnostics, Personalis, BillionToOne, Quest Diagnostics, Adaptive Biotechnologies, Illumina, NeoGenomics, Myriad Genetics, Laboratory Corporation of America, and BostonGene
10-K for FY2025, filed Mar 3, 2026Our competitors in tissue-based molecular profiling include Foundation Medicine (Roche) and Tempus. In addition, some academic centers…View ↗
Loading...